

REMARKS

Claims 1-62 were pending in the application. Claims 2-62 have been cancelled without prejudice. New claims 63-77 have been added. Support for the claim amendments and the new claims can be found in the specification as filed and, for example, originally filed claims. Thus, upon the entry of the foregoing amendment, claims 1 and 63-77 will remain pending.

No new matter has been added. The foregoing claim amendments and cancellations were made solely to expedite prosecution of the present application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

Restriction Requirement

In the Office Action mailed January 9, 2007, the Examiner required election of one of the following inventions under 35 U.S.C. §121:

- Group I: Claims 1-20, drawn to a bispecific molecule, classified in class 530, subclass 388.2.
- Group II: Claims 21-39, drawn to a method of treating or preventing a disease associated with presence of a pathogenic agent in an animal, classified in class 530, subclass 388.4.
- Group III: Claims 40-53, drawn to a method of treating or preventing viral infection, classified in class 530, subclass 388.3.
- Group IV: Claims 54, 56 and 57-61, drawn to a method of reducing the symptoms of exposure to anthrax spores, classified in class 588, subclass 319.
- Group V: Claims 55, 56 and 57-61, drawn to a method of treating symptoms of exposure to anthrax spores, classified in class 424, subclass 130.1.
- Group VI: Claims 62, drawn to a method of enhancing the protective effect of a non-neutralizing antibody, classified in class 530, subclass 389.5.

Additionally, the Examiner required a further species election of:

a.) If Applicants elect group I:

- 1a. One of the bispecific molecules from claims 1, 19, or 20
- 1aa. One of the subspecies of organisms from claims 4, 5, or 6

b.) If Applicants elect group II:

1a. One of the species of organisms from claims 29, 30, 31, or 32

Accordingly, Applicants hereby elect group I, drawn to a bispecific molecule, for continued examination. Please note that new claims 63-76 are directed to a bispecific molecule and should be contained in group I.


With respect to the species elections requested by the Examiner if Group I were elected, Applicants elect the species 1a of an E11 antibody as the anti-CR1 antibody from claim 19 *for search purposes only*. Claims 1, 63, and 65-77 are readable on the elected species. With respect to the election of a subspecies of an organism from claims 4, 5, or 6, Applicants elect the subspecies of an antibody that recognizes a bacterial antigen *for search purposes only*. Claims 1 and 63-77 are readable on the elected species. It is Applicants' understanding that upon the allowance of a generic claim, they will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R §1.141 *et seq.* It is Applicants' further understanding that claims directed to methods of using the elected compositions will be subject to rejoinder if the composition claims from which they depend are found allowable.

CONCLUSION

If a telephone conversation with Applicants' attorney would expedite prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Dated: February 9, 2007

Respectfully submitted,

By 
Megan E. Williams
Registration No.: 43,270
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicants